Login / Signup

As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner.

Daojia MiaoJian ShiZhiyong XiongWen XiaoXiangui MengQingyang LvKairu XieHongmei YangXiaoping Zhang
Published in: Cancer cell international (2022)
TFHs and Tregs were considered as prognostic biomarkers and RUFY4 was an immunotherapeutic predictor of ccRCC patients in a PDL1-Related manner.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • patient reported outcomes